would allow the government to guarantee between $750 million and $3 billion to companies that produce new FDA-approved treatments for the top threats. The payment size would depend on how novel the treatment is, and the money would be spread out over five to 10 years. Any purchases by federal agencies, like Medicare, would be deducted from the subscription amount so the government doesn’t pay twice. States and private health facilities would order and pay as they normally do.
Chatterjee’s lab in Boulder is working on a nanoparticle to try to keep existing antibiotics working a little longer. Some bacteria essentially shut themselves down temporarily when certain antibiotics are present, meaning they don’t metabolize the drug and can reawaken once it’s out of the patient’s system. The nanoparticles keep the bacteria from shutting down, allowing the existing antibiotics to do their jobs, at least in petri dishes.
The U.S. health care system was making some progress on reducing deaths from resistant bacteria before the pandemic, according to a 2019 report from the CDC. It estimated deaths had fallen about 18% since 2013, though that’s based on less-than-precise data.
Better come up with new antibiotics. We’re no good with the first idea.
It’s the price to pay for living in fear of bacteria and prescribing antibiotics like they are candy. You can thank big pharma who doesn’t care as they sit back and count their dump trucks full of money
Have they considered antibiotics?